A disruptive technology to tackle brain cancer and glioblastoma
News
Hemerion One of 20 Emerging Healthtechs of 2023 for its Combination Therapy in the Treatment of Glioblastoma
Hemerion's technology is cited as an example of a major trend in healthcare innovation in StartUs Insights' 2023 report. Since 2014, StartUs Insights has analyzed the evolution of nearly 4… ...
Glioblastoma clinical trial in Pittsburgh: Heliance® devices shipped to the USA
Hemerion's teams have taken the first step towards setting up a new clinical trial in the USA, with the shipment of a complete batch of Heliance® devices and its drug… ...
Hemerion announces FDA clearance of IND application for its treatment of glioblastoma
Hemerion has received clearance from the US Food and Drug Administration (FDA) for the investigational new drug application (IND) for its Pentalafen® / Heliance® drug-device combination product for the treatment… ...
Stay tuned to our clinical advances
They talk about us
